Biomedical Innovation

biomedical innovation

Biomedical Innovation


Duke-Margolis, in partnership with FDA and a wide array of other stakeholder groups, is focused on improving the process of medical product development and regulatory review to increase the treatment options available to patients and the value that these products can introduce into the health care system.

Our works centers on the following areas:

  • Regulatory Science
  • Medical Product Pricing and Payment
  • Real-World Evidence
  • Artificial Intelligence and Clinical-Decision Making Software